Infrastructure project: U.S. medicinal leech breeding facility
Biosecurity, traceability, and resilience for U.S. clinical supply.
The supply chain problem
U.S. hospitals currently depend on a small number of suppliers for FDA-cleared medicinal leeches. Three 510(k) clearances exist (K040187, K132958, K140907), all held by two entities. Breeding and cultivation occur primarily outside the United States, making supply vulnerable to import disruptions, regulatory changes in exporting countries, and international shipping delays.
For time-sensitive surgical applications — particularly flap salvage and replantation — supply interruptions can directly affect patient outcomes. Hospitals with active leech therapy protocols require predictable, on-demand availability.
Why domestic supply matters
Reliability for hospitals and research
Protocolized, time-sensitive workflows benefit from stable availability and predictable logistics. Domestic production eliminates international transit variables and customs delays.
Supply chain resilience
Reduced dependency on imports improves continuity for clinical programs and prospective registries. A domestic facility provides redundancy against single-source failure.
Quality and traceability
Domestic breeding allows end-to-end documentation from breeding stock through delivery — supporting lot tracking, adverse event investigation, and regulatory audit requirements.
Research enablement
Consistent, characterized leech populations support standardized research protocols. Variable source quality is a known confounder in hirudotherapy studies.
Facility concept
The proposed facility is designed around controlled-environment aquaculture principles adapted for medicinal leech husbandry:
| Component | Description |
|---|---|
| Controlled environment | Temperature, humidity, and water quality monitoring with automated alerts |
| Quarantine flow | Incoming breeding stock quarantine with health screening before integration into production |
| Lot tracking | Individual batch identification from cocoon through shipment, supporting recall capability |
| Chain-of-custody | Documentation from breeding to delivery, aligned with hospital procurement audit requirements |
| Waste handling | Biohazard waste protocols per U.S. Public Health Command guidelines |
Nonprofit access model
The facility operates under a public-benefit supply model consistent with ASH’s nonprofit mission. Pricing and distribution policies are documented transparently. The model is designed to avoid commercial ambiguity and support grant-funded research programs.
Institutional purchasers (hospitals, research institutions) are the primary audience. Direct-to-consumer distribution is not part of the current model.
Status and milestones
Project milestones
- Facility siting and lease
- Build-out and environmental controls installation
- Breeding stock acquisition and quarantine
- Quality management system documentation
- First production batch validation
- Institutional pilot supply agreements
Proposed facility location
Stanton, CA 90680 USA
Southern California location selected for climate suitability, proximity to academic medical centers, and logistics infrastructure.
Disclaimer
Last updated: March 14, 2026